Literature DB >> 26842595

In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.

Matthew D Harwood1, Brahim Achour2, Sibylle Neuhoff2, Matthew R Russell2, Gordon Carlson2, Geoffrey Warhurst2, Amin Rostami-Hodjegan2.   

Abstract

Relative expression factors (REFs) are used to scale in vitro transporter kinetic data via in vitro-in vivo extrapolation linked to physiologically based pharmacokinetic (IVIVE-PBPK) models to clinical observations. Primarily two techniques to quantify transporter protein expression are available, immunoblotting and liquid chromatography-tandem mass spectrometry. Literature-collated REFs ranged from 0.4 to 5.1 and 1.1 to 90 for intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), respectively. The impact of using human jejunum-Caco-2 REFs for P-gp (REFiP-gp) and BCRP (REFiBCRP), generated from the same samples and using different proteomic methodologies from independent laboratories, on PBPK outcomes was assessed. A 5-fold decrease in REFiP-gp for a single oral dose of digoxin resulted in a 1.19- and 1.31-fold higher plasma area under the curve and Cmax, respectively. All generated REFiP-gp values led to simulated digoxin Cmax values within observed ranges; however, combining kinetic data generated from a different laboratory with the 5-fold lower REFiP-gp could not recover a digoxin-rifampicin drug-drug interaction, emphasizing the necessity to obtain transporter-specific kinetic estimates and REFs from the same in vitro system. For a theoretical BCRP compound, with absorption taking place primarily in the jejunum, a decrease in the REFiBCRP from 2.22 (University of Manchester) to 1.11 (Bertin Pharma) promoted proximal intestinal absorption while delaying tmax 1.44-fold. Laboratory-specific differences in REF may lead to different IVIVE-PBPK outcomes. To understand the mechanisms underlying projected pharmacokinetic liabilities, it is important to assess the potential impact of bias on the generation of REFs on an interindividual basis within a target population.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26842595     DOI: 10.1124/dmd.115.067777

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper.

Authors:  Bhagwat Prasad; Brahim Achour; Per Artursson; Cornelis E C A Hop; Yurong Lai; Philip C Smith; Jill Barber; Jacek R Wisniewski; Daniel Spellman; Yasuo Uchida; Michael A Zientek; Jashvant D Unadkat; Amin Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2019-07-26       Impact factor: 6.875

Review 2.  Critical Issues and Optimized Practices in Quantification of Protein Abundance Level to Determine Interindividual Variability in DMET Proteins by LC-MS/MS Proteomics.

Authors:  Deepak Kumar Bhatt; Bhagwat Prasad
Journal:  Clin Pharmacol Ther       Date:  2017-09-25       Impact factor: 6.875

3.  Targeted LC-MS/MS Proteomics-Based Strategy To Characterize in Vitro Models Used in Drug Metabolism and Transport Studies.

Authors:  Meijuan Xu; Neha Saxena; Marc Vrana; Haeyoung Zhang; Vineet Kumar; Sarah Billington; Cyrus Khojasteh; Scott Heyward; Jashvant D Unadkat; Bhagwat Prasad
Journal:  Anal Chem       Date:  2018-09-28       Impact factor: 6.986

4.  Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.

Authors:  Christopher Rowbottom; Alicia Pietrasiewicz; Taras Tuczewycz; Richard Grater; Daniel Qiu; Sudarshan Kapadnis; Patrick Trapa
Journal:  Pharmacol Res Perspect       Date:  2021-04

5.  Duodenum Intestine-Chip for preclinical drug assessment in a human relevant model.

Authors:  Magdalena Kasendra; Raymond Luc; Jianyi Yin; Dimitris V Manatakis; Gauri Kulkarni; Carolina Lucchesi; Josiah Sliz; Athanasia Apostolou; Laxmi Sunuwar; Jenifer Obrigewitch; Kyung-Jin Jang; Geraldine A Hamilton; Mark Donowitz; Katia Karalis
Journal:  Elife       Date:  2020-01-14       Impact factor: 8.140

6.  Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children.

Authors:  Laurens F M Verscheijden; Carlijn H C Litjens; Jan B Koenderink; Ron H J Mathijssen; Marcel M Verbeek; Saskia N de Wildt; Frans G M Russel
Journal:  PLoS Comput Biol       Date:  2021-03-04       Impact factor: 4.475

7.  Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.

Authors:  Soo Hyeon Bae; Wan-Su Park; Seunghoon Han; Gab-Jin Park; Jongtae Lee; Taegon Hong; Sangil Jeon; Dong-Seok Yim
Journal:  Korean J Physiol Pharmacol       Date:  2018-04-25       Impact factor: 2.016

Review 8.  Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.

Authors:  Kunal S Taskar; Venkatesh Pilla Reddy; Howard Burt; Maria M Posada; Manthena Varma; Ming Zheng; Mohammed Ullah; Arian Emami Riedmaier; Ken-Ichi Umehara; Jan Snoeys; Masanori Nakakariya; Xiaoyan Chu; Maud Beneton; Yuan Chen; Felix Huth; Rangaraj Narayanan; Dwaipayan Mukherjee; Vaishali Dixit; Yuichi Sugiyama; Sibylle Neuhoff
Journal:  Clin Pharmacol Ther       Date:  2019-12-31       Impact factor: 6.875

9.  Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine.

Authors:  Narciso Couto; Zubida M Al-Majdoub; Stephanie Gibson; Pamela J Davies; Brahim Achour; Matthew D Harwood; Gordon Carlson; Jill Barber; Amin Rostami-Hodjegan; Geoffrey Warhurst
Journal:  Drug Metab Dispos       Date:  2020-01-20       Impact factor: 3.922

10.  Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin.

Authors:  Zubida M Al-Majdoub; Brahim Achour; Narciso Couto; Martyn Howard; Yasmine Elmorsi; Daniel Scotcher; Sarah Alrubia; Eman El-Khateeb; Areti-Maria Vasilogianni; Noura Alohali; Sibylle Neuhoff; Lutz Schmitt; Amin Rostami-Hodjegan; Jill Barber
Journal:  FEBS Lett       Date:  2020-12-03       Impact factor: 3.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.